PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY

por de Botton, Stéphane, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel, Rousselot, Philippe, Rizzieri, David, Liesveld, Jane, Fenaux, Pierre, Braun, Thorsten, Pigneux, Arnaud, Peterlin, Pierre, Paul, Sofia, Rajagopal, Nisha, Carulli, John, Roth, David, Volkert, Angela, Malak, Tanya Abdul, Kelly, Michael, Klimek, Virginia, Stein, Eytan
Publicado 2023

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

por de Botton, Stéphane, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel J., Rousselot, Philippe, Rizzieri, David A., Liesveld, Jane L., Fenaux, Pierre, Braun, Thorsten, Banos, Anne, Jurcic, Joseph G., Sekeres, Mikkael A., Savona, Michael R., Roboz, Gail J., Bixby, Dale, Madigan, Kate, Volkert, Angela, Stephens, Kristin, Kang-Fortner, Qing, Baker, Kristen, Paul, Sofia, McKeown, Michael, Carulli, John, Eaton, Matthew, Hodgson, Graeme, Fiore, Christopher, Kelly, Michael J., Roth, David A., Stein, Eytan M.
Publicado 2022